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Abstract
Background: Adult patients with congenital heart disease (CHD) usually find their exercise
capacity satisfactory. However, objective evaluation is important for diagnostic and prognostic
purposes. The aim of this study was to evaluate exercise capacity using cardiopulmonary
exercise tests and measurement of serum B-type natriuretic peptide (BNP) levels in adult
patients with CHDs, both in the entire study cohort and in subjects with individual types of
cardiac lesions, as well as to verify the relation between BNP level and cardiac performance.
Methods: The study group included 265 patients (136 males; mean age 34.4 ± 11.6 years)
173 of whom were operated on at the mean age of 9.2 ± 7.3 years. They represented the
following types of CHD: 72 patients — surgically corrected coarctation of the aorta,
62 — surgically corrected tetralogy of Fallot, 28 — Ebstein anomaly, 26 — patent atrial septal
defect, 24 — Eisenmenger syndrome, 20 — uncorrected or palliated complex cyanotic lesions,
11 — corrected transposition of the great arteries (TGA), 14 — TGA after Senning operation,
and 8 — common ventricle after Fontana operation. The control group consisted of 39 healthy
individuals (17 males) with a mean age of 35.8 ± 9.3 years.
Results: According to NYHA classification, 207 patients were recognized as representing
class I symptoms, 47 subjects class II, and 11 class III. Cardiopulmonary exercise revealed
significantly reduced exercise capacity in adults with CHD in general, compared to control
subjects: maximal oxygen uptake (VO2max) was 23.3 ± 6.9 vs. 33.6 ± 7.2 mL/kg/min,
respectively (p = 0.00001); maximum heart rate at peak exercise (HRmax) —161.1 ± 33.2 vs.
179.6 ± 12.3 bpm (p = 0.00001); respiratory workload (VE/VCO2slope) — 35.7 ± 9.7 vs.
26.3 ± 3.1 (p = 0.00001); and forced vital capacity (FVC) — 3.8 ± 1.1 vs. 4.6 ± 0.7 L (p =
= 0.00003). Various degrees of peak VO2max reduction were observed across the spectrum of
CHD. Patients after repair of aortic coarctation demonstrated the highest VO2max (26.8 ±
± 6.6 mL/kg/min), and the lowest was demonstrated by patients with Eisenmenger syndrome
(12.8 ± 4.8; ANOVA p = 0.00001). Serum BNP levels in the study group were higher than in
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the controls: 55.4 ± 67.5 vs. 13.9 ± 13.7 pg/mL, respectively (p = 0.00001). Various degrees
of BNP level increase were found across the spectrum of CHD. Patients after repair of aortic
coarctation demonstrated the lowest BNP level (24.8 pg/mL), and the highest level was found
in patients with cyanotic defects (120.7 pg/mL; ANOVA p = 0.00001). BNP levels across the
NYHA classes were as follows: I — 35.7 pg/mL, II — 94.1 pg/mL, and III — 225.6 pg/mL.
BNP levels showed negative correlation with VO2max (r = –0.525, p = 0.0001), FVC (r =
= –0.349, p = 0.00001), FEV1 (r = –0.335, p= 0.00001), and positive correlation with
VE/VCO2slope (r = 0.447, p = 0.00001).
Conclusions: The exercise capacity of patients with CHD is, in general, compromised, most
strikingly in patients suffering from pulmonary hypertension and cyanosis. Serum BNP levels
in these subjects are increased and correlate well with exercise capacity. BNP level is higher in
patients with cyanotic CHDs. (Cardiol J 2009; 16, 2: 133–141)
Key words: cardiopulmonary exercise testing, congenital heart disease,
natriuretic peptide type B
Introduction
As a result of long-term adaptation, adult pa-
tients with congenital heart disease (CHD) usually
self-report their exercise capacity as satisfactory
[1–5]. However, heart failure (HF) remains the
major clinical problem in this group of patients. The
pathophysiology of heart failure in adults with CHD
is complex, with primary causes related to impair-
ment of both left and/or right ventricular function,
as well as to great vessel abnormalities [1, 6–14].
Pulmonary hypertension often adds to or affects the
pathophysiology of heart failure [10, 12, 15]. Thus,
the assessment of heart failure severity in such
a clinically diverse population is quite difficult, but
still necessary as it has important therapeutic im-
plications [2, 3, 10, 12, 16, 17]. It has been shown
that, similarly to patients with left ventricular he-
art failure [18], cardiopulmonary exercise testing is
also an objective diagnostic and prognostic tool in
adult patients with CHDs [1, 10, 12, 19–21].
B-type natriuretic peptide (BNP) concentration is
another validated diagnostic and prognostic marker
of heart failure [19, 22]. Recently, the diagnostic re-
levance of BNP in certain types of CHD has been
shown [6, 10, 17, 23–28]. However, we are not awa-
re of any reports on the relationship between se-
rum BNP levels and cardiac performance determi-
ned by means of cardiopulmonary exercise test in
the general population of adult patients with CHD.
The aim of this study was to evaluate exercise
capacity in adults with CHD using cardiopulmona-
ry exercise testing, and measurement of serum
BNP levels in the entire study cohort and in patients
with different types of cardiac lesions. Additionally,
the possible correlations between BNP levels and
cardiac performance were explored.
Methods
The study group was selected from the popu-
lation of patients followed-up at the Congenital
Heart Disease Outpatient Clinic of the 1st Depart-
ment of Cardiology of the Medical University of
Poznan. It consisted of 265 patients (136 males)
aged 19–65 years (mean 34.4 ± 11.6 years);
173 (65.3%) of them were operated on at the age of
1–42 years (mean 9.2 ± 7.3 years), 9–34 years ear-
lier (mean 21.8 ± 7.4 years). In Table 1, the clini-
cal characteristics of the group are detailed; the
study cohort included: 72 patients with surgically
corrected coarctation of the aorta (CoAo), 62 pa-
tients with surgically corrected tetralogy of Fallot
(ToF), 28 patients with Ebstein anomaly, 26 patients
with patent atrial septal defect (ASD), 24 patients
with Eisenmenger syndrome, 20 patients with un-
corrected or palliated complex cyanotic lesions
(ToF, transposition of the great arteries, double
inlet left ventricle, tricuspid atresia), 11 patients
with corrected transposition of the great arteries,
14 patients with transposition of the great arteries
after Senning operation, and 8 patients with common
ventricle after Fontana operation. In  53 (20.0%) pa-
tients, arterial blood oxygen saturation (SO2) was
below 90%. Pulmonary hypertension, found on
echocardiography (right ventricular end-systolic
pressure > 30 mm Hg), was confirmed in 58 sub-
jects (21.9%). None of the patients was in the early
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postoperative period. The control group comprised
39 healthy individuals (17 males) aged 23–58 years
(mean 35.8 ± 9.3 years). New York Heart Associa-
tion (NYHA) functional class was determined ba-
sed on clinical evaluation and the patient’s self-re-
ported symptoms at the time of the exercise test.
All patients had a sinus rhythm (patients with atrial
fibrillation/flutter were excluded); neither arrhyth-
mia nor pulmonary disease were found in these
patients, serum creatinine levels were below
140 mg/ml, and aspartate aminotransferase levels
did not exceed twice the upper limit of the normal.
Some patients were on diuretics and ACE-
-inhibitors, and 3.7% of patients were on beta-
-blockers, which were continued at the time of stu-
dy for ethical reasons. Arterial hypertension was
diagnosed in 29 patients.
Laboratory analysis
In all patients, blood samples were drawn from
an antecubital vein prior to the exercise test after
a 15 min rest in supine position. The concentrations
of brain natriuretic peptide in human serum were
determined with the use of immunoradiometric as-
say kit — Shionoria BNP (Schering CIS bio interna-
tional). The radioactivity was measured for 1 minu-
te with a gamma scintillation counter type NZ 335.
Cardiopulmonary exercise test
All patients carried out a maximal, symptom-
limited (fatigue and/or dyspnea) treadmill exercise
test according to modified Bruce protocol (adding
to standard Bruce protocol stage 0–3 min; 1.7 km/h,
at 5% grading), whereas the control subjects tests
were carried out according to standard Bruce
protocol. Patients were encouraged to continue
with the test for as long as their respiratory quotient
exceeded one. The maximal oxygen consumption
(peakVO2), carbon dioxide production (VCO2), and
minute ventilation (VE) were measured using bre-
ath by breath gas analysis (Sensor Medics, model
Vmax29). The system was calibrated with a stan-
dard gas mixture of known concentrations before
each test. A standard 12-lead electrocardiogram was
continuously recorded. Blood pressure was measu-
red every two minutes using a cuff sphygmomano-
meter. Peak VO2 was defined as a mean of values
measured within the last 20 s of exercise, and
expressed as both mL/kg/min and mL/min, and as the
percentage of predicted peak oxygen consumption.
The ventilation/carbon dioxide slope (VE/VCO2slope)
was calculated automatically by computer system
Vmax29. Spirometry was performed in all subjects
before cardiopulmonary exercise test with measu-
rement of forced vital capacity (FVC) and forced
expiratory volume in one second (FEV1), and was
calculated as a percentage of the predicted values,
adjusted for age, sex, and body mass. The evaluation
of the cardiopulmonary exercise test was performed
by investigators that were blinded to the results of
the BNP measurements.
Statistical analysis
Continuous variables following normal distri-
bution were expressed as mean and standard
deviation, and those not normally distributed as me-
dian and range. Variables following normal distri-
bution were compared using t-Student test for unpa-
ired samples. Otherwise, the Mann-Whithney U
test was used. For comparisons involving more than
Table 1. Demographic and clinical characteristics of analyzed group of patients.
Congenital heart diseases No. of Gender of Age No. of Age at NYHA
patients  male (%)  (years)  operated on  time of class
surgery I/II/III
(years)
Operated coarctation of aorta 72 44 (61%) 32.5±10.4 72 (100%) 10.6±8.9 70/2/0
Ebstein anomaly 28 21 (75%) 39.4±11.8 0 – 26/3/1
Tetralogy of Fallot 62 32 (51.6%) 29.7±9.3 62 (100%) 7.6± 4.9 60/1/1
Atrial septal defect 26 10 (38.5%) 43.2±8.9 0 – 26/0/0
Eisenmenger syndrome 24 5 (20.8%) 44.1±14.1 0 0 0/19/6
Complex cyanotic lesions 20 10 (50.0%) 33.6±11.1 14 (70.0%) 12.3±11.4 2/13/5
TGA after Senning operation 14 6 (42.8%) 26.1±14.8 14 (100%) 4.3±3.8 12/2/0
Corrected TGA 11 6 (54.5%) 36.1±12.1 3 (27.3%) 20.6±11.2 6/5/0
Common ventricle after 8 2 (25%) 23.8±3.8 8 (100%) 8.7±3.1 5/2/1
Fontan operation
TGA — transposition of the great arteries
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two groups, ANOVA with Tukey post-hoc test fol-
lowing Shapiro-Wilk test for normality and Leven’s
test for homogeneity of variance or Kruskal-Wallis
test with Dunn’s multiple comparisons test were
used. To assess the degree of correlation between
variables, Spearman’s Rank Correlation or Pear-
son’s Correlation statistics (depending on variable
distribution) were used. Results are presented as
the coefficient of correlation (r). A p value
< 0.05 was considered significant. Statistical analy-
sis was carried out using Statistica software rev. 8.
Informed consent was obtained from each pa-
tient and the study protocol conforms to the ethi-
cal guidelines of the 1975 Declaration of Helsinki
as reflected in a priori approval of the institution’s
human research committee.
Results
Among all the study patients, 207 (78.1%) self-
-assessed their exercise capacity as satisfactory
(NYHA I), 47 (17.7%) as moderately limited (NYHA II),
and the remaining 11 (4.1%) as significantly com-
promised (NYHA III).
Cardiopulmonary exercise test results are
summarized in Table 2. In the general group of CHD
adults, VO2max and VO2max% was significantly lo-
wer then measured in the control group (p =
= 0.00001 and p = 0.00001, respectively). The
maximum heart rate at peak exercise was signifi-
cantly lower than in the healthy individuals
(p = 0.00001 and p = 0.00001, respectively). The
peak systolic blood pressure was higher in the con-
trol group (p = 0.05). A significant difference was
observed with respect to the index of the respira-
tory workload (VE/VCO2slope), which was higher
in the study group than in the controls (p =
= 0.00001). The main respiratory quotient in the
analyzed patients was significantly lower than in the
controls (p = 0.0001).
Spirometry
Values of pulmonary elasticity parameters,
FVC and FVC%, were lower in patients with CHD than
in the control group (p = 0.00003 and p = 0.00001,
respectively). Moreover, markers of airway ob-
struction, FEV1 and FEV1%, were significantly lo-
wer than in the control group (p = 0.00001 and
p = 0.00001, respectively).
The impact of cardiac lesion type on exercise
capacity: a varying degree of peak VO2 reduction
(expressed as mL/kg/min, mean ± SD) was found
across the spectrum of congenital heart disease
types (Fig. 1). Patients after repair of the aortic
coarctation demonstrated the highest peak oxygen
consumption (26.8 ± 6.6). Lower VO2 was observed
in patients with corrected ToF (24.9 ± 5.7), patent
ASD (24.6 ± 4.8), corrected transposition of the
great arteries (24.2 ± 6.6), Ebstein anomaly (22.3 ±
± 5.0), transposition of the great arteries after Sen-
ning surgery (21.1 ± 5.9), common ventricle after
Fontan operation (19.5 ± 3.8) and complex cyanotic
Table 2. Comparison of cardiopulmonary exercise test parameters and brain natriuretic peptide (BNP)
levels between studied patients and control group.
Study group (n = 265) Control group (n =39) P
Age (years) 34.4±11.6 35.8±9.3 0.20
BNP [pg/mL] 55.4±67.5 13.9±13.7 0.00001
SO2 (%) 94.8±7.3 99.1±0.9 0.00001
VO2 [mL/kg/min] 23.3±6.9 33.6±7.2 0.00001
VO2% 62.0±15.9 88.9±14.8 0.00001
VE/VCO2 35.7±9.7 26.3±3.1 0.00001
HRmax [bpm] 161.1±33.2 179.6±12.3 0.00001
HRmax% 88.0±13.2 100.1±7.2 0.00001
FVC [L] 3.8±1.1 4.6±0.7 0.00003
FVC% 90.2±17.5 103.2±9.1 0.00001
FEV1 [L] 3.0±0.8 3.7±2.4 0.00001
FEV1% 81.6±21.6 99.2±10.7 0.00001
BPmax [mm Hg] 165.5±26.5 170.6±15.3 0.05
Respiratory quotient 1.06±0.05 1.1±0.07 0.0007
SO2 — saturation, VO2 — peak oxygen consumption, VE/VCO2slope — ventilatory equivalent for carbon dioxide, FVC — forced vital capacity,
FEV1 — forced expiratory volume in one second, BPmax — peak exercise blood pressure, HRmax — peak exercise heart rate
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lesions (15.9 ± 3.4), and the lowest VO2 was seen
in patients with Eisenmenger syndrome (12.8 ±
± 4.8; ANOVA p = = 0.00001). These differences
remained significant after inclusion of age as a po-
ssible confounder in an ANCOVA (p = 0.0001). Si-
gnificant differences in VO2 were observed between
individuals with Eisenmenger syndrome and CoAo
(p = 0.00001), corrected ToF (p = 0.00001), Ebstein
anomaly (p = 0.00003), ASD (p = 0.00001), correc-
ted transposition of the great arteries (p = 0.0003),
transposition of the great arteries after Senning
operation (p = 0.003) and between complex cyano-
tic lesions and CoAo (p = 0.00002), corrected ToF
(p = 0.0007), ASD (p = 0.001), and corrected trans-
position of the great arteries (p = 0.03).
Serum BNP levels in the study group were
higher than in controls: 55.4 ± 67.5 vs. 13.9 ±
± 13.7 pg/mL (p = 0.00001). They did not exceed
the commonly recognized normal value of 100 pg
in 226 patients (85.3% of the study population).
The impact of cardiac lesion type on serum
BNP concentration: A varying degree of serum BNP
level increase (expressed as pg/ml and median, ran-
ge) was found across the spectrum of congenital
heart disease types (Fig. 2). Patients after repair of
aortic coarctation demonstrated the lowest BNP
level (24.8; 1.4–299.9); higher concentrations of this
peptide were seen in patients with Ebstein anomaly
(26.7; 5.2–178.2), after correction of ToF (29.3;
6.2–159.4), transposition of the great arteries after
Senning operation (32.8; 15.2–321.4), ASD (35.7;
13.8–276.1), corrected transposition of the great ar-
teries (42.1; 11.3–180.2), Eisenmenger syndrome
(75.6; 14.2–343.9), after Fontan surgery (95.5; 27.9–
–278.8), and in patients with complex cyanotic di-
sease (120.7; 28.8––456.5; ANOVA p = 0.00001).
These differences remained significant after adjusting
for age (ANCOVA p = 0.0001). Significant differen-
ces in BNP concentrations were observed betwe-
en Eisenmenger syndrome and CoAo (p = 0.00001),
repaired ToF (p = 0.006), and Ebstein anomaly
(p = 0.02), as well as between complex cyanotic de-
fects and the latter three (p = 0.00003, p = 0.0008,
p = 0.002, respectively).
Serum BNP increased, along with the severi-
ty of heart failure (Fig. 2), being 35.7 pg/mL in
NYHA I individuals, 94.1 pg/mL in NYHA II, and
225.6 pg/mL in the most symptomatic patients.
There were significant differences between BNP
level in NYHA I vs. NYHA II patient groups and
between NYHA I vs. NYHA III patient groups (p =
= 0.00001, p = 0.00001)
Analysis of serum BNP levels and cardiopul-
monary exercise test parameters revealed a nega-
tive correlation between BNP levels and peak oxy-
gen uptake VO2max (r = –0.525, p = 0.0001), FVC
(r = –0.349, p = 0.00001), and FEV1 (r = –0.335,
p = 0.00001); a positive correlation was observed
between BNP levels and VE/VCO2 slope (r = 0.447,
p = 0.00001) (Fig. 3–6). No significant correlations
between BNP concentration and current patient age
and age at time of operation were found.
Figure 1. Maximum oxygen uptake (VO2) for each con-
genital heart disease; CoAo — coarctation of aorta, ToF
— operated tetralogy of Fallot, ASD — patent atrial
septal defect, CCTGA — corrected transposition of the
great arteries, Ebstein — Ebstein anomaly, Senning —
transposition of the great arteries after Senning opera-
tion, Fontan — common ventricle after Fontan opera-
tion, cyanotic CHD — cyanotic congenital heart dise-
ases, Eisenmenger — Eisenmenger syndrome.
Figure 2. Serum brain natriuretic peptide (BNP) levels in
each congenital heart disease (for abbreviations see Fig. 1).
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Discussion
The majority of study patients with CHD were
asymptomatic or presented with minor signs of
heart failure. As many as 17.7% of subjects had
NYHA class II symptoms, and only 4.1% had NYHA
class III. Such a good subjective appraisal of exer-
cise capacity in this population remains consistent
with our previous observations [2–5] as well as with
the reports of other investigators [1, 29]. However,
true exercise capacity in our patients was significan-
tly compromised, similarly to the findings reported
in recently published studies [1, 7, 10, 14, 19, 30].
The mechanism of heart failure in adults with CHD
is complex, depending on the severity of cardiova-
scular disease, concomitant pulmonary pathology,
and the presence of cyanosis, myocardial damage
resulting from inadequate protection during cardiac
surgery, arrhythmia, neurohormonal activity, and
comorbidities such as ischemic heart disease or
hypertension [1, 7–13, 15, 31]. Our study showed
that heart failure was less pronounced in patients
after repair of coarctation of the aorta, marked in
subjects with cyanotic defects, and most severe in
subjects with Eisenmenger syndrome; this is also
consistent with observations reported by Royal
Brompton Hospital investigators [19]. Similar ana-
lysis reported by Fredriksen et al. [1] suggested the
lowest exercise capacity in patients with heart of
single ventricular physiology, and the highest
capacity in patients after correction of ToF; this
study, however, lacked patients with corrected co-
arctation of the aorta and subjects with secondary
pulmonary hypertension. Diller et al. [19] showed
Figure 3. Correlation between BNP levels and VO2max
in patients with congenital heart disease.
Figure 4. Correlation between BNP levels and VE/VCO2
slope in patients with congenital heart disease.
Figure 5. Correlation between BNP levels and FVC in
patients with congenital heart disease.
Figure 6. Correlation between BNP levels and FEV1 in
patients with congenital heart disease.
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that most significant predictors of poor maximum
oxygen consumption are low maximum heart rate
at peak exercise, low forced expiratory volume in
one second, high NYHA functional class, and, most
of all, the presence of pulmonary hypertension and
cyanosis. This may explain our finding of most se-
vere heart failure in patients with Eisenmenger
syndrome. Due to the anatomical complexity of
congenital heart disease and the pathomechanisms
of resultant heart failure causing diagnostic pro-
blems, investigators are looking for reliable and
easily accessible diagnostic and prognostic markers
in adults with CHD. The previously-mentioned in-
vestigators from London [19] suggested that maxi-
mum oxygen consumption may serve as such
a marker, documenting increased risk of hospitali-
zation and mortality if less than 15.5 mL/kg/min.
This criterion was met by 32 of our patients (12.2%).
Dimopoulos et al. [13] reported ventilatory equiva-
lent ratio for carbon dioxide (VE/VCO2slope) abo-
ve 38 to be a risk factor of mortality in adults with
non-cyanotic CHD. In our study 48 (22.6%) of
212 such selected patients met that criterion. In the
majority of adults with CHD, reduced chronotropic
response significantly affected heart failure preva-
lence [1, 11, 20, 30]. According to Diller et al. [14]
failure to reach 80% of age- and sex-adjusted pre-
dicted maximum heart rate at peak exercise is ano-
ther risk factor of mortality in this population. In
our cohort, 57 patients (21.6%) did not reach such
a heart rate threshold. Our analyses showed that
despite self-reported good general feeling, about
1/5 of patients with CHD were at high risk of mortality.
Another diagnostic and prognostic risk factor
in heart failure is serum concentration of B-type
natriuretic peptide. Increased BNP level is the re-
sult of increased heart chamber wall stress, resul-
ting form increased blood volume typical of heart
failure [10, 32, 33]. Other stimuli for BNP secre-
tion have been documented to be pulmonary hy-
pertension and cyanosis [34–37]. Our group of CHD
patients had high BNP levels, significantly exce-
eding those in healthy controls; however, most of
them did not exceed the accepted normal value.
According to published data BNP levels are incre-
ased in most types of CHD with both volume and
pressure overload of left [5, 24, 38] or right ven-
tricles [16, 17, 23, 27, 28, 35, 39] as well as of the
single ventricular heart [17, 29, 39].
Analysis has shown significant correlation be-
tween serum BNP and cardiopulmonary exercise
test parameters, namely maximum oxygen con-
sumption (VO2max) and ventilation to perfusion
ratio (VE/VCO2slope). A similar relationship between
BNP and above mentioned parameters was confir-
med in patients after total repair of tetralogy of
Fallot [3]. Other investigators found, in a similar
group of patients, significant correlation between
BNP levels and maximum oxygen consumption [40].
This association was also confirmed in our analy-
ses in adults with patent ASD [2]. Bolger et al. [6]
came to similar conclusions in various types of CHD
in adults. However, an association between BNP
level and VO2 was not confirmed by Dore et al. [16]
in subjects with corrected transposition of the gre-
at arteries and transposition of the great arteries
after Mustard operation. Our study has also shown
significant negative correlation between BNP level
and pulmonary elasticity (FVC) and obstruction
(FEV1) parameters. An association between B-type
natriuretic hormone levels and FVC was also confir-
med in patients after repair of tetralogy of Fallot [3].
Results of this observation may confirm the signi-
ficant role of pulmonary pathology in the pathoge-
nesis of heart failure in CHD adults, suggested by
other authors [1, 15, 41].
At the same time, no significant correlation
between BNP concentration and current patient age
and age at the time of surgery was found. The early
success of cardiac surgery, particularly in patients
with complex heart defects, helped them to reach
adulthood. However, such a group remains unpro-
tected against progression of complications resul-
ting from sequels as well as the consequences of
the surgery performed, that both worsen heart fa-
ilure with age [42].
B-type natriuretic peptide levels increased
along with the severity of heart failure expressed
as NYHA functional class, regardless of CHD ana-
tomy, which is consistent with other reports [6, 24,
27, 28]. On the other hand, the anatomical backgro-
und of CHD somehow influences serum BNP level.
Our analysis revealed lower BNP concentration in
patients with a history of repair of coarctation of the
aorta, being the highest in subjects with complex
cyanotic defects. In addition, the distribution resem-
bles that of the maximum oxygen consumption pro-
file (VO2) in individual CHDs. There is a trend of
BNP changes in various CHDs, and may result from
the complexity of cardiac anomalies and progres-
sing heart failure as a consequence.
Conclusions
1. Exercise capacity of adult patients with CHD
is compromised with the highest severity in pa-
tients with defects that involve pulmonary hy-
pertension and cyanosis.
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2. Serum BNP levels in these subjects are incre-
ased and closely correlated with exercise ca-
pacity. The B-type natriuretic peptide level is
highest in patients with cyanotic congenital
heart disease.
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